{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:51:03Z","timestamp":1785901863609,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006203","name":"Johnson Space Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jpba.2022.115004","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T11:23:15Z","timestamp":1660389795000},"page":"115004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Analytical and functional similarity of biosimilar Elizaria\u00ae with eculizumab reference product"],"prefix":"10.1016","volume":"220","author":[{"given":"Valentina","family":"Gusarova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Degterev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lyagoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Simonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Smolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Taran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahim","family":"Shukurov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpba.2022.115004_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","article-title":"aHUS caused by complement dysregulation: new therapies on the horizon","volume":"26","author":"Waters","year":"2011","journal-title":"Pedia Nephrol."},{"key":"10.1016\/j.jpba.2022.115004_bib2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2022.115004_bib3","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jpba.2022.115004_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40259-021-00492-9","article-title":"Analytical similarity assessment of ABP 959 in comparison with eculizumab reference product","volume":"35","author":"Hutterer","year":"2021","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.jpba.2022.115004_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4161\/mabs.19868","article-title":"Galactosylation variations in marketed therapeutic antibodies","volume":"4","author":"Raju","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2022.115004_bib6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.TP.0000142673.32394.95","article-title":"Immune response, accommodation, and tolerance to transplantation carbohydrate antigens","volume":"78","author":"Galili","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jpba.2022.115004_bib7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/138920108786786411","article-title":"Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins","volume":"9","author":"Beck","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jpba.2022.115004_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/glycob\/10.5.477","article-title":"Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics","volume":"10","author":"Raju","year":"2000","journal-title":"Glycobiology"},{"key":"10.1016\/j.jpba.2022.115004_bib9","unstructured":"WHO Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs), Annex 2, Technical Report Series No. 1004. https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/who_trs_1004_web_annex_2.pdf?sfvrsn=7f119245_3&download=true (accessed 2017\u201301-16)."},{"key":"10.1016\/j.jpba.2022.115004_bib10","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations. Guidance for Industry. https:\/\/www.fda.gov\/media\/125484\/download (accessed 2019-05)."},{"key":"10.1016\/j.jpba.2022.115004_bib11","unstructured":"U.S. Department of Health and Human Services, Food and drug administration, center for drug evaluation and research, center for biologics evaluation and research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. https:\/\/www.fda.gov\/media\/135612\/download (accessed 2015-4)."},{"key":"10.1016\/j.jpba.2022.115004_bib12","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-first-version_en.pdf (accessed 2018-02\u201327)."},{"key":"10.1016\/j.jpba.2022.115004_bib13","unstructured":"C.M.C. Biotech Working Group. A-MAb: A Case Study in Bioprocess Development. Emeryville, CA: CASSS, 2009. https:\/\/qbdworks.com\/wp-content\/uploads\/2014\/06\/A-MabCaseStudyVersion.pdf (accessed 2009\u201310-30)."},{"key":"10.1016\/j.jpba.2022.115004_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"issue":"8","key":"10.1016\/j.jpba.2022.115004_bib16","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","article-title":"Mapping of the C1q binding site on rituxan","volume":"164","author":"Idusogie","year":"2000","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jpba.2022.115004_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/10543406.2016.1272606","article-title":"Development of statistical methods for analytical similarity assessment","volume":"27","author":"Tsong","year":"2017","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.jpba.2022.115004_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/BS.S84141","article-title":"Challenging issues in assessing analytical similarity in biosimilar studies","volume":"5","author":"Chow","year":"2015","journal-title":"Biosimilars"},{"issue":"5","key":"10.1016\/j.jpba.2022.115004_bib19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.4161\/mabs.29883","article-title":"In vitro and in vivo modifications of recombinant and human IgG antibodies","volume":"6","author":"Liu","year":"2014","journal-title":"mAbs"},{"issue":"23","key":"10.1016\/j.jpba.2022.115004_bib20","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1074\/jbc.M709987200","article-title":"Human IgG2 antibodies display disulfide-mediated structural isoforms","volume":"283","author":"Wypych","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2022.115004_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/mabs.23392","article-title":"Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression","volume":"5","author":"Buchanan","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.jpba.2022.115004_bib22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/bit.26265","article-title":"Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability","volume":"114","author":"Chung","year":"2017","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jpba.2022.115004_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ab.2008.07.016","article-title":"Free sulfhydryl measurement as an indicator of antibody stability","volume":"382","author":"Lacy","year":"2008","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.jpba.2022.115004_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.32362\/2410-6593-2021-16-1-76-87","article-title":"A comparison of originator and biosimilar biotherapeutics of eculizumab monoclonal antibody with Intact mass measurement and Middle up mass spectrometry approaches","volume":"16","author":"Degterev","year":"2021","journal-title":"Fine Chem. Technol."},{"issue":"6","key":"10.1016\/j.jpba.2022.115004_bib25","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4161\/mabs.1.6.10185","article-title":"IgG2m4, an engineered antibody isotype with reduced Fc function","volume":"1","author":"Zhiqiang","year":"2009","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.jpba.2022.115004_bib26","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1002\/jps.23284","article-title":"Evaluation of effects of Fc domain high-mannose glycan on antibody stability","volume":"101","author":"Lu","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jpba.2022.115004_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4161\/mabs.20450","article-title":"Increased serum clearance of oligomannose species present on a human IgG1 molecule","volume":"4","author":"Alessandri","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2022.115004_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/glycob\/cwl057","article-title":"Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types","volume":"17","author":"Kanda","year":"2007","journal-title":"Glycobiology"},{"issue":"2","key":"10.1016\/j.jpba.2022.115004_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/19420862.2015.1117719","article-title":"Glycan analysis of therapeutic glycoproteins","volume":"8","author":"Zhang","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2022.115004_bib30","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.4049\/jimmunol.1501458","article-title":"A complement-optimized EGFR antibody improves cytotoxic functions of polymorphonuclear cells against tumor cells","volume":"195","author":"Derer","year":"2015","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jpba.2022.115004_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/glycob\/cwn120","article-title":"The effect of Fc glycan forms on human IgG2 antibody clearance in humans","volume":"19","author":"Chen","year":"2009","journal-title":"Glycobiology"},{"issue":"5","key":"10.1016\/j.jpba.2022.115004_bib32","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1021\/ac300234a","article-title":"Analysis of nonhuman N-glycans as the minor constituents in recombinant monoclonal antibody pharmaceuticals","volume":"84","author":"Maeda","year":"2012","journal-title":"Anal. Chem."},{"issue":"6","key":"10.1016\/j.jpba.2022.115004_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4161\/mabs.2.6.13333","article-title":"Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats","volume":"2","author":"Khawli","year":"2010","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.jpba.2022.115004_bib34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4161\/mabs.22066","article-title":"Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice","volume":"4","author":"Filipe","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2022.115004_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4236\/abb.2013.44A004","article-title":"Fc receptors: cell activators of antibody functions","volume":"4","author":"Rosales","year":"2013","journal-title":"Adv. Biosci. Biotechnol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:23:35Z","timestamp":1760001815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522004253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"alternative-id":["S0731708522004253"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115004","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical and functional similarity of biosimilar Elizaria\u00ae with eculizumab reference product","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115004"}}